Oral Oncology
Volume 46, Issue 1 , Pages 42-48 , January 2010

Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of resveratrol complexed with 2-hydroxypropyl-β-cyclodextrin

  • Giovanni Nicolao Berta

      Affiliations

    • Department of Clinical and Biological Sciences, Pharmacology Unity, University of Turin, I-10043 Orbassano, Italy
    • Corresponding Author InformationCorresponding author. Address: Department of Clinical and Biological Sciences, Ospedale San Luigi Gonzaga, I-10043 Orbassano, Italy. Tel.: +39 0116705446; fax: +39 0119038639.
    • These authors contributed equally to this work.
    • ,
  • Paolina Salamone

      Affiliations

    • Department of Clinical and Biological Sciences, Pharmacology Unity, University of Turin, I-10043 Orbassano, Italy
    • These authors contributed equally to this work.
    • ,
  • Andrea Elio Sprio

      Affiliations

    • Department of Clinical and Biological Sciences, Pharmacology Unity, University of Turin, I-10043 Orbassano, Italy
    • ,
  • Federica Di Scipio

      Affiliations

    • Department of Clinical and Biological Sciences, Pharmacology Unity, University of Turin, I-10043 Orbassano, Italy
    • ,
  • Lucy Marcela Marinos

      Affiliations

    • Department of Clinical and Biological Sciences, Pharmacology Unity, University of Turin, I-10043 Orbassano, Italy
    • ,
  • Simona Sapino

      Affiliations

    • Department of Drug Science and Technology, University of Turin, I-10125 Torino, Italy
    • ,
  • Maria Eugenia Carlotti

      Affiliations

    • Department of Drug Science and Technology, University of Turin, I-10125 Torino, Italy
    • ,
  • Roberta Cavalli

      Affiliations

    • Department of Drug Science and Technology, University of Turin, I-10125 Torino, Italy
    • ,
  • Francesco Di Carlo

      Affiliations

    • Department of Clinical and Biological Sciences, Pharmacology Unity, University of Turin, I-10043 Orbassano, Italy

Received 25 August 2009 ,Revised 21 October 2009 ,Accepted 21 October 2009.

References 

  1. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45(4–5):309–316
  2. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36(10):575–580
  3. Splieth CH, Sumnig W, Bessel F, John U, Kocher T. Prevalence of oral mucosal lesions in a representative population. Quintessence Int. 2007;38(1):23–29
  4. Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Systematic review of randomized trials for the treatment of oral leukoplakia. J Dent Educ. 2002;66(8):896–902
  5. Papadimitrakopoulou VA, William WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res. 2008;14(7):2095–2101
  6. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275(5297):218–220
  7. Kundu JK, Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett. 2008;269(2):243–261
  8. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493–506
  9. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarker Prev. 2007;16(6):1246–1252
  10. Yu C, Shin YG, Chow A, Li Y, Kosmeder JW, Lee YS, et al. Human, rat, and mouse metabolism of resveratrol. Pharm Res. 2002;19(12):1907–1914
  11. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK. High absorption but very low bioavailability of oral resveratrol in umans. Drug Metab Dispos. 2004;32(12):1377–1382
  12. Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res. 2005;49(5):472–481
  13. Hung CF, Lin YK, Huang ZR, Fang JY. Delivery of resveratrol, a red wine polyphenol, from solutions and hydrogels via the skin. Biol Pharm Bull. 2008;31(5):955–962
  14. Nash RA. Cyclodextrins. In:  Rowe RC,  Ysheskey P,  Owen SC editor. Handbook of pharmaceutical excipients. 5th ed.. London: Royal Pharmaceutical Society of Great Britain; 2006;p. 217–221
  15. Del Valle EMM. Cyclodextrins and their uses: a review. Process Biochem. 2004;39(9):1033–1046
  16. Hara T, Arima H, Hirayama F, Uekama K. Enhanced bioavailability of a new thiazolidine derivative FPFS-410, an antidiabetic and lipid-lowering drug, after oral administration of its hydroxypropyl-beta-cyclodextrin complex to bile duct-cannulated rats. J Pharm Sci. 2006;95(8):1771–1782
  17. Carrier RL, Miller LA, Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release. 2007;123(2):78–99
  18. Uekama K, Hirayama F, Arima H. Recent aspect of cyclodextrin-based drug delivery system. J Incl Phenom Macrocycl Chem. 2006;56:3–8
  19. Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2007;329(1–2):1–11
  20. Odukoya O, Schwartz J, Weichselbaum R, Shklar G. An epidermoid carcinoma cell line derived from hamster DMBA-induced buccal pouch tumors. J Natl Cancer Inst. 1983;71(6):1253–1264
  21. Salley JJ. Experimental carcinogenesis in the cheek pouch of the Syrian hamster. J Dent Res. 1954;33(2):253–262
  22. Vairaktaris E, Spyridonidou S, Papakosta V, Vylliotis A, Lazaris A, Perrea D, et al. The hamster model of sequential oral oncogenesis. Oral Oncol. 2008;44(4):315–324
  23. Mognetti B, Di Carlo F, Berta GN. Animal models in oral cancer research. Oral Oncol. 2006;42(5):448–460
  24. Sapino S, Carlotti ME, Caron G, Ugazio E, Cavalli R. In silico design, photostability and biological properties of the complex resveratrol/hydroxypropyl-b-cyclodextrin. J Incl Phenom Macrocycl Chem. 2009;63:171–180
  25. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988;48(17):4827–4833
  26. Lippman SM, Lee JJ. Reducing the “risk” of chemoprevention: defining and targeting high risk – 2005 AACR cancer research and prevention foundation award lecture. Cancer Res. 2006;66(6):2893–2903
  27. Docherty JJ, Smith JS, Fu MM, Stoner T, Booth T. Effect of topically applied resveratrol on cutaneous herpes simplex virus infections in hairless mice. Antiviral Res. 2004;61(1):19–26
  28. Loftsson T, Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm. 2001;225(1–2):15–30
  29. Gould S, Scott RC. 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol. 2005;43(10):1451–1459
  30. Pirola L, Fröjdö S. Resveratrol: one molecule, many targets. IUBMB Life. 2008;60(5):323–332
  31. Chen YK, Lin LM. Placental glutathione-S-transferase isoenzyme expression in polycyclic aromatic hydrocarbon-induced hamster buccal pouch mucosa. Oral Oncol. 1998;34(3):180–185
  32. Chen YK, Lin LM. Immunohistochemical expression of inducible nitric oxide synthase in DMBA-induced hamster buccal pouch carcinogenesis. Oral Oncol. 2000;36(2):221–224
  33. Yan M, Schneider J, Gear R, Lu F, LaDow K, Warshawsky D, et al. Expression of angiogenic factors is upregulated in DMBA-induced rat mammary pathologies. Pathobiology. 2004;71(5):253–260
  34. Banerjee S, Bueso-Ramos C, Aggarwal BB. Suppression of 7,12-dimethylbenz[a]anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. 2002;62(17):4945–4954
  35. Gillison ML. Current topics in the epidemiology of oral cavity and oropharyngeal cancers. Head Neck. 2007;29(8):779–792
  36. Puga A, Ma C, Marlowe JL. The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways. Biochem Pharmacol. 2009;77(4):713–722
  37. Currier N, Solomon SE, Demicco EG, Chang DL, Farago M, Ying H, et al. Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicol Pathol. 2005;33(6):726–737
  38. Ciolino HP, Daschner PJ, Yeh GC. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res. 1998;58(24):5707–5712
  39. Casper RF, Quesne M, Rogers IM, Shirota T, Jolivet A, Milgrom E, et al. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol. 1999;56(4):784–790
  40. Szaefer H, Krajka-Kuźniak V, Baer-Dubowska W. The effect of initiating doses of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene on the expression of PAH activating enzymes and its modulation by plant phenols. Toxicology. 2008;251(1–3):28–34
  41. Koutsas C, Sarigiannis Y, Stavropoulos G, Liakopoulou-Kyriakides M. Conjugation of resveratrol with RGD and KGD derivatives. Protein Pept Lett. 2007;14(10):1014–1020
  42. Schipper RG, Silletti E, Vingerhoeds MH. Saliva as research material: biochemical, physicochemical and practical aspects. Arch Oral Biol. 2007;52(12):1114–1135
  43. Schwartz J, Shklar G, Reid S, Trickler D. Prevention of experimental oral cancer by extracts of Spirulina-Dunaliella algae. Nutr Cancer. 1988;11(2):127–134
  44. Chabner BA, Roberts TG. Chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5(1):65–72

PII: S1368-8375(09)00943-9

doi: 10.1016/j.oraloncology.2009.10.007

Oral Oncology
Volume 46, Issue 1 , Pages 42-48 , January 2010

Article Tools

* Image Usage & Resolution